2. UroToday Home
  3. Conference Highlights
  4. ESMO 2020
  5. ESMO 2020 Prostate Cancer

ESMO 2020

ESMO Virtual Congress 2020: NRG Oncology’s GU007 (NADIR): Niraparib with Standard Combination with ADT and Radiotherapy in High-Risk Prostate Cancer

(UroToday.com) High-risk localized prostate cancer is managed with either surgery, or the combination of radiation therapy plus androgen deprivation therapy (ADT). Despite treatment with curative intent, approximately half of patients experience recurrence, with significant prostate cancer specific mortality. The NADIR trial aims to test the hypothesis that the addition of PARP inhibition to definitive radiotherapy plus ADT will improve outcomes of men with high-risk localized prostate cancer. This is based on preclinical data suggesting that PARP inhibition serves as a radiosensitizer regardless of the mutation status of homologous recombination genes such as BRCA2.


To test this hypothesis, the authors propose a phase 1 lead-in study followed by a randomized phase 2 trial. Patients with Gleason 9 or 10 localized prostate cancer and PSA less than 150 who have not received prior ADT will be eligible for the phase 1 lead-in. The lead-in will consist of escalating doses of the PARP inhibitor niraparib. The schema for the lead-in and anticipated recruitment numbers are shown below.


ESMO2020_._Zumsteg_1.png

Once the maximum tolerated dose of niraparib is established, the phase 2 study will begin. The schema for the phase 2 randomized trial is shown below.

ESMO2020_._Zumsteg_2.png


The primary outcome in the phase 2 study is compare the number of patients considered disease free (PSA < 0.1 in this study) between treatment arms. Secondary endpoints will include survival, locoregional progression, rates of development of metastatic disease, and exploratory tissue and blood biomarker studies to identify correlates of resistance or response to therapy.

In both arms, radiation will be delivered in either a standard (79.2Gy in 44 fractions) or hypofractionated (70Gy is 28 fractions) manner along with 45 Gy in 25 fractions to the pelvic lymph nodes. Brachytherapy is not allowed. Testosterone suppression will be accomplished per investigator discretion and will start 2-4 months prior to radiation therapy.

Presented by: Zachary S. Zumsteg, MD, Assistant Professor of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA

Written by: Alok Tewari, MD, PhD, Medical Oncologist at the Dana-Farber Cancer Institute, at the 2020 European Society for Medical Oncology Virtual Congress (#ESMO20), September 19th-September 21st, 2020.